|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
The global cytomegalovirus (CMV) infections market has been forecast to increase at a compound annual growth rate (CAGR) of 6.29% over the next eight years, increasing from a valuation of $685.50 million in 2011 to hit a market value of $1.12 billion by 2019.
Human cytomegalovirus is a species of virus that belongs to the viral family known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV and is alternatively known as Human herpesvirus 5 (HHV-5).
Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.
Although they may be found throughout the body, HCMV infections are frequently associated with the salivary glands.
HCMV infection is typically unnoticed in healthy people, but can be life-threatening for the immunocompromised, such as HIV-infected persons, organ transplant recipients, or new born infants.
Roche has a strong presence in the CMV market with Valcyte, which is the only branded product for the treatment of CMV infections. The company is likely to maintain its competitive position until the generalisation of Valcyte in 2013 in the US and its patent expiry in 2015 in Europe.
The current market competition in the CMV market is weak, as Valcyte is the only branded drug for the treatment of CMV. Valcyte is a prodrug of ganciclovir with improved bioavailability, and is considered to be efficacious and safe for the treatment of CMV patients.
The CMV market will see the entrance of new companies that focus on three important strategies: first, companies focusing on novel mechanisms of action beyond DNA polymerase inhibitors; second, companies targeting transplant patients; and third, companies developing prophylactic products (40% of the pipeline products are being developed for CMV prophylaxis).
These strategies are expected to provide a distinct opportunity for pharmaceutical companies to build up their commercial presence in the CMV infections market.
For more information on the cytomegalovirus infections market, see the latest research: Cytomegalovirus Infections Market
Follow us on Twitter @CandMResearch
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
Use our skills and global network of researchers and consultants to help find and source the business information you need.
Contact us now on 00 44 (0) 203 0868600 or "enquiries @ companiesandmarkets.com" to discuss you requirements and we can provide you with a research solution at suprisingly efficient rates and timelines.
Sometimes we can even find the information you require for free.
We are offering our clients substantial savings on the best research available during January. Please contact us either via email or by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600.